View Item 

Show simple item record

ACR Appropriateness Criteria® Aggressive Nonmelanomatous Skin Cancer of the Head and Neck
dc.contributor.authorKoyfman, Shlomo A.en_US
dc.contributor.authorCooper, Jay S.en_US
dc.contributor.authorBeitler, Jonathan J.en_US
dc.contributor.authorBusse, Paul M.en_US
dc.contributor.authorJones, Christopher U.en_US
dc.contributor.authorMcDonald, Mark W.en_US
dc.contributor.authorQuon, Harryen_US
dc.contributor.authorRidge, John A.en_US
dc.contributor.authorSaba, Nabil F.en_US
dc.contributor.authorSalama, Joseph K.en_US
dc.contributor.authorSiddiqui, Farzanen_US
dc.contributor.authorSmith, Richard V.en_US
dc.contributor.authorWorden, Francisen_US
dc.contributor.authorYao, Minen_US
dc.contributor.authorYom, Sue S.en_US
dc.date.accessioned2016-02-01T18:48:24Z
dc.date.available2017-04-04T14:50:43Zen
dc.date.issued2016-02en_US
dc.identifier.citationKoyfman, Shlomo A.; Cooper, Jay S.; Beitler, Jonathan J.; Busse, Paul M.; Jones, Christopher U.; McDonald, Mark W.; Quon, Harry; Ridge, John A.; Saba, Nabil F.; Salama, Joseph K.; Siddiqui, Farzan; Smith, Richard V.; Worden, Francis; Yao, Min; Yom, Sue S. (2016). "ACR Appropriateness Criteria® Aggressive Nonmelanomatous Skin Cancer of the Head and Neck." Head & Neck 38(2): 175-182.en_US
dc.identifier.issn1043-3074en_US
dc.identifier.issn1097-0347en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/117005
dc.description.abstractBackgroundAggressive nonmelanomatous skin cancer (NMSC) of the head and neck presents an increasingly common therapeutic challenge for which prospective clinical trials are lacking.MethodsThe American College of Radiology Appropriateness Criteria are evidence‐based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well‐established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.ResultsThe American College of Radiology Expert Panel on Radiation Oncology – Head and Neck Cancer developed consensus recommendations for guiding management of aggressive NMSC.ConclusionMultidisciplinary assessment is vital to guiding the ideal use of surgery, radiation, and systemic therapy in this disease. © 2016 Wiley Periodicals, Inc. Head Neck 38: 175–182, 2016en_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherhigh risken_US
dc.subject.otherhead necken_US
dc.subject.othernonmelanomatous skin canceren_US
dc.subject.otherAppropriateness Criteriaen_US
dc.subject.otherradiotherapyen_US
dc.titleACR Appropriateness Criteria® Aggressive Nonmelanomatous Skin Cancer of the Head and Necken_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/117005/1/hed24171.pdf
dc.identifier.doi10.1002/hed.24171en_US
dc.identifier.sourceHead & Necken_US
dc.identifier.citedreferenceKim S, Eleff M, Nicolaou N. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck. Head Neck 2011; 33: 286 – 288.en_US
dc.identifier.citedreferenceAvril MF, Auperin A, Margulis A, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 1997; 76: 100 – 106.en_US
dc.identifier.citedreferenceSmeets NW, Krekels GA, Ostertag JU, et al. Surgical excision vs Mohs' micrographic surgery for basal‐cell carcinoma of the face: randomised controlled trial. Lancet 2004; 364: 1766 – 1772.en_US
dc.identifier.citedreferenceLocke J, Karimpour S, Young G, Lockett MA, Perez CA. Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol Phys 2001; 51: 748 – 755.en_US
dc.identifier.citedreferenceRupprecht R, Lippold A, Auras C, et al. Late side‐effects with cosmetic relevance following soft X‐ray therapy of cutaneous neoplasias. J Eur Acad Dermatol Venereol 2007; 21: 178 – 185.en_US
dc.identifier.citedreferenceSchulte KW, Lippold A, Auras C, et al. Soft x‐ray therapy for cutaneous basal cell and squamous cell carcinomas. J Am Acad Dermatol 2005; 53: 993 – 1001.en_US
dc.identifier.citedreferenceKwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys 2004; 60: 406 – 411.en_US
dc.identifier.citedreferenceRio E, Bardet E, Ferron C, et al. Interstitial brachytherapy of periorificial skin carcinomas of the face: a retrospective study of 97 cases. Int J Radiat Oncol Biol Phys 2005; 63: 753 – 757.en_US
dc.identifier.citedreferenceJackson JE, Dickie GJ, Wiltshire KL, et al. Radiotherapy for perineural invasion in cutaneous head and neck carcinomas: toward a risk‐adapted treatment approach. Head Neck 2009; 31: 604 – 610.en_US
dc.identifier.citedreferenceLin C, Tripcony L, Keller J, et al. Perineural infiltration of cutaneous squamous cell carcinoma and basal cell carcinoma without clinical features. Int J Radiat Oncol Biol Phys 2012; 82: 334 – 340.en_US
dc.identifier.citedreferenceWang JT, Palme CE, Morgan GJ, Gebski V, Wang AY, Veness MJ. Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: improved survival with the addition of adjuvant radiotherapy. Head Neck 2012; 34: 1524 – 1528.en_US
dc.identifier.citedreferenceEbrahimi A, Clark JR, Lorincz BB, Milross CG, Veness MJ. Metastatic head and neck cutaneous squamous cell carcinoma: defining a low‐risk patient. Head Neck 2012; 34: 365 – 370.en_US
dc.identifier.citedreferenceMendenhall WM, Amdur RJ, Hinerman RW, Cognetta AB, Mendenhall NP. Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope 2009; 119: 1994 – 1999.en_US
dc.identifier.citedreferenceWarden KF, Parmar H, Trobe JD. Perineural spread of cancer along the three trigeminal divisions. J Neuroophthalmol 2009; 29: 300 – 307.en_US
dc.identifier.citedreferenceSekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal‐cell carcinoma. N Engl J Med 2012; 366: 2171 – 2179.en_US
dc.identifier.citedreferenceBernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005; 27: 843 – 850.en_US
dc.identifier.citedreferenceBlanchard P, Baujat B, Holostenco V, et al. Meta‐analysis of chemotherapy in head and neck cancer (MACH‐NC): a comprehensive analysis by tumour site. Radiother Oncol 2011; 100: 33 – 40.en_US
dc.identifier.citedreferenceLewis CM, Glisson BS, Feng L, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 2012; 18: 1435 – 1446.en_US
dc.identifier.citedreferenceHeath CH, Deep NL, Nabell L, et al. Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2013; 85: 1275 – 1281.en_US
dc.identifier.citedreferenceMaubec E, Petrow P, Scheer–Senyarich I, et al. Phase II study of cetuximab as first‐line single‐drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011; 29: 3419 – 3426.en_US
dc.identifier.citedreferenceGordon Spratt EA, Carucci JA. Skin cancer in immunosuppressed patients. Facial Plast Surg 2013; 29: 402 – 410.en_US
dc.identifier.citedreferenceLeisenring W, Friedman DL, Flowers ME, Schwartz JL, Deeg HJ. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006; 24: 1119 – 1126.en_US
dc.identifier.citedreferenceMoloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population‐based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006; 154: 498 – 504.en_US
dc.identifier.citedreferenceLott DG, Manz R, Koch C, Lorenz RR. Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation 2010; 90: 683 – 687.en_US
dc.identifier.citedreferenceSmith KJ, Hamza S, Skelton H. Histologic features in primary cutaneous squamous cell carcinomas in immunocompromised patients focusing on organ transplant patients. Dermatol Surg 2004; 30 ( 4 Pt 2 ): 634 – 641.en_US
dc.identifier.citedreferenceWisgerhof HC, Edelbroek JR, de Fijter JW, et al. Subsequent squamous‐ and basal‐cell carcinomas in kidney‐transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation 2010; 89: 1231 – 1238.en_US
dc.identifier.citedreferenceBuell JF, Hanaway MJ, Thomas M, Alloway RR, Woodle ES. Skin cancer following transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005; 37: 962 – 963.en_US
dc.identifier.citedreferenceManyam B, Saxton JP, Reddy CA, et al. Inferior outcomes in immunosuppressed patients with high risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy paper presented at: 2014 Multidisciplinary Head and Neck Cancer Symposium; Scottsdale, Arizona.en_US
dc.identifier.citedreferenceOddone N, Morgan GJ, Palme CE, et al. Metastatic cutaneous squamous cell carcinoma of the head and neck: the immunosuppression, treatment, extranodal spread, and margin status (ITEM) prognostic score to predict outcome and the need to improve survival. Cancer 2009; 115: 1883 – 1891.en_US
dc.identifier.citedreferenceLang PG Jr, Braun MA, Kwatra R. Aggressive squamous carcinomas of the scalp. Dermatol Surg 2006; 32: 1163 – 1170.en_US
dc.identifier.citedreferenceEuvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin‐cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329 – 339.en_US
dc.identifier.citedreferenceHoogendijk–van den Akker JM, Harden PN, Hoitsma AJ, et al. Two‐year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol 2013; 31: 1317 – 1323.en_US
dc.identifier.citedreferenceZwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65: 263 – 279; quiz 280.en_US
dc.identifier.citedreferenceGhanadan A, Abbasi A, Rabet M, Abdollahi P, Abbasi M. Characteristics of mixed type basal cell carcinoma in comparison to other BCC subtypes. Indian J Dermatol 2014; 59: 56 – 59.en_US
dc.identifier.citedreferenceVico P, Fourez T, Nemec E, Andry G, Deraemaecker R. Aggressive basal cell carcinoma of head and neck areas. Eur J Surg Oncol 1995; 21: 490 – 497.en_US
dc.identifier.citedreferenceNCCN Clinical Practice Guidelines in Oncology. Basal cell and squamous cell skin cancers. Version 2.2014. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf. Accessed March 26, 2014.en_US
dc.identifier.citedreferenceLee WR, Mendenhall WM, Parsons JT, Million RR. Radical radiotherapy for T4 carcinoma of the skin of the head and neck: a multivariate analysis. Head Neck 1993; 15: 320 – 324.en_US
dc.identifier.citedreferenceMendenhall WM, Amdur RJ, Hinerman RW, et al. Skin cancer of the head and neck with perineural invasion. Am J Clin Oncol 2007; 30: 93 – 96.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hed24171.pdf
Size:
115.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.